TREACE MEDICAL CONCEPTS INC (TMCI)
US89455T1097 - Common Stock
Taking everything into account, TMCI scores 4 out of 10 in our fundamental rating. TMCI was compared to 192 industry peers in the Health Care Equipment & Supplies industry. The financial health of TMCI is average, but there are quite some concerns on its profitability. TMCI is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year TMCI has reported negative net income.
TMCI had a negative operating cash flow in the past year.
TMCI had negative earnings in each of the past 5 years.
TMCI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TMCI has a Return On Assets (-19.66%) which is in line with its industry peers.
TMCI has a Return On Equity of -35.90%. This is comparable to the rest of the industry: TMCI outperforms 54.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.66% | ||
| ROE | -35.9% | ||
| ROIC | N/A |
ROA(3y)-20.43%
ROA(5y)-17.61%
ROE(3y)-42.96%
ROE(5y)-163.9%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMCI has a better Gross Margin (81.20%) than 92.71% of its industry peers.
TMCI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TMCI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.25%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TMCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
TMCI has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, TMCI has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.44 indicates that TMCI is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.44, TMCI is doing good in the industry, outperforming 68.75% of the companies in the same industry.
A Debt/Equity ratio of 0.38 indicates that TMCI is not too dependend on debt financing.
TMCI has a Debt to Equity ratio (0.38) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.44 |
ROIC/WACCN/A
WACC10.23%
2.3 Liquidity
A Current Ratio of 4.40 indicates that TMCI has no problem at all paying its short term obligations.
TMCI's Current ratio of 4.40 is fine compared to the rest of the industry. TMCI outperforms 63.02% of its industry peers.
TMCI has a Quick Ratio of 3.76. This indicates that TMCI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.76, TMCI is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.4 | ||
| Quick Ratio | 3.76 |
3. Growth
3.1 Past
TMCI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.19%.
TMCI shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.92%.
Measured over the past years, TMCI shows a very strong growth in Revenue. The Revenue has been growing by 48.27% on average per year.
EPS 1Y (TTM)-5.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-25%
Revenue 1Y (TTM)31.92%
Revenue growth 3Y48.28%
Revenue growth 5YN/A
Revenue growth Q2Q25%
3.2 Future
TMCI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.03% yearly.
The Revenue is expected to grow by 20.11% on average over the next years. This is a very strong growth
EPS Next Y-16.75%
EPS Next 2Y-1%
EPS Next 3Y1%
EPS Next 5Y20.03%
Revenue Next Year20.26%
Revenue Next 2Y19.16%
Revenue Next 3Y18.37%
Revenue Next 5Y20.11%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TMCI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TMCI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1%
EPS Next 3Y1%
5. Dividend
5.1 Amount
TMCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TREACE MEDICAL CONCEPTS INC
NASDAQ:TMCI (4/26/2024, 7:19:56 PM)
After market: 10.4 0 (0%)10.4
+0.1 (+0.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap644.18M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.66% | ||
| ROE | -35.9% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.4 | ||
| Quick Ratio | 3.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-5.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-16.75%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)31.92%
Revenue growth 3Y48.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y